fluoxetine has been researched along with Bilateral Headache in 24 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study is to investigate the clinical therapeutic effects and safety of treating mild or moderate depression with somatic symptoms with electroacupuncture combined with Fluoxetine." | 9.14 | Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine. ( Chen, LP; Duan, DM; Tu, Y; Wu, ZJ, 2009) |
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 9.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "This study is the first double-blind placebo-controlled trial of fluoxetine for chronic daily headache (CDH) and migraine." | 9.07 | Double-blind trial of fluoxetine: chronic daily headache and migraine. ( Lake, AE; Saper, JR; Silberstein, SD; Winters, ME, 1994) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 6.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| "This study is to investigate the clinical therapeutic effects and safety of treating mild or moderate depression with somatic symptoms with electroacupuncture combined with Fluoxetine." | 5.14 | Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine. ( Chen, LP; Duan, DM; Tu, Y; Wu, ZJ, 2009) |
| "Fifty-five outpatients with DSM-IV major depressive disorder and a confirmed history of intolerance to fluoxetine (mean final dose = 24." | 5.10 | Citalopram treatment of fluoxetine-intolerant depressed patients. ( Calabrese, JR; Londborg, PD; Shelton, MD; Thase, ME, 2003) |
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 5.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "Common adverse events associated with initiating fluoxetine treatment in depressed patients, including nausea, insomnia, nervousness, and somnolence, resolve in the majority of patients and become significantly less frequent with continued treatment over a 6-month period." | 5.09 | Changes in adverse events reported by patients during 6 months of fluoxetine therapy. ( Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999) |
| "This study is the first double-blind placebo-controlled trial of fluoxetine for chronic daily headache (CDH) and migraine." | 5.07 | Double-blind trial of fluoxetine: chronic daily headache and migraine. ( Lake, AE; Saper, JR; Silberstein, SD; Winters, ME, 1994) |
| "Outpatients with recurrent unipolar depression (DSM-IV criteria; N = 1096) were randomly assigned in a 3:1 ratio to 10 weeks of treatment with venlafaxine ER or fluoxetine." | 2.73 | The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. ( Ahmed, S; Dunner, DL; Ferguson, JM; Friedman, ES; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kocsis, JH; Kornstein, SG; Musgnung, J; Nemeroff, CB; Ninan, PT; Pedersen, RD; Rothschild, AJ; Schatzberg, AF; Shelton, RC; Thase, ME; Trivedi, MH; Yan, B; Zajecka, JM, 2007) |
| " Discontinuation for lack of efficacy was lower in BP II (5%) than in UP (12%) patients (p = not significant [NS]), whereas dropouts for adverse events were similar in BP II (11%) and UP (9%) patients." | 2.69 | Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. ( Amsterdam, JD; Beasley, C; Fawcett, J; Garcia-España, F; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Schweizer, E, 1998) |
| " There were 188 adverse events: insomnia, dizziness, headache, nausea, dry mouth and myoclonic jerks were the most common." | 2.68 | Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. ( Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S, 1996) |
| "or fluoxetine p." | 2.67 | Efficacy and safety of morning versus evening fluoxetine administration. ( Beasley, CM; Bosomworth, JC; Usher, RW, 1991) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 2.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| " The hysteresis between peak blood levels and maximal pharmacodynamic effects suggests formation of an active metabolite." | 2.66 | Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses. ( Grünberger, J; Saletu, B, 1985) |
| " We hypothesized that in patients taking 20 mg/day, efficacy would be maintained but the incidence of adverse events would be lower." | 2.41 | Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. ( Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 12 (50.00) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, DM | 1 |
| Tu, Y | 1 |
| Chen, LP | 1 |
| Wu, ZJ | 1 |
| Calabrese, JR | 1 |
| Londborg, PD | 1 |
| Shelton, MD | 1 |
| Thase, ME | 2 |
| Yu, BP | 1 |
| Chong, YS | 1 |
| Maguire, GA | 1 |
| Menza, MA | 1 |
| Dobkin, RD | 1 |
| Marin, H | 1 |
| Martenyi, F | 1 |
| Brown, EB | 1 |
| Caldwell, CD | 1 |
| Keller, MB | 1 |
| Trivedi, MH | 1 |
| Shelton, RC | 1 |
| Kornstein, SG | 2 |
| Nemeroff, CB | 1 |
| Friedman, ES | 1 |
| Gelenberg, AJ | 1 |
| Kocsis, JH | 1 |
| Dunner, DL | 1 |
| Hirschfeld, RM | 1 |
| Rothschild, AJ | 1 |
| Ferguson, JM | 1 |
| Schatzberg, AF | 1 |
| Zajecka, JM | 1 |
| Pedersen, RD | 1 |
| Yan, B | 1 |
| Ahmed, S | 1 |
| Musgnung, J | 1 |
| Ninan, PT | 1 |
| Saper, JR | 2 |
| Silberstein, SD | 2 |
| Lake, AE | 2 |
| Winters, ME | 2 |
| Hawley, CJ | 1 |
| Quick, SJ | 1 |
| Ratnam, S | 1 |
| Pattinson, HA | 1 |
| McPhee, S | 1 |
| Haddad, P | 1 |
| Zajecka, J | 2 |
| Tracy, KA | 1 |
| Mitchell, S | 1 |
| Freeman, SA | 1 |
| Zisook, S | 1 |
| Peterkin, J | 1 |
| Goggin, KJ | 1 |
| Sledge, P | 1 |
| Atkinson, JH | 1 |
| Grant, I | 1 |
| Wheatley, DP | 1 |
| van Moffaert, M | 1 |
| Timmerman, L | 1 |
| Kremer, CM | 1 |
| Amsterdam, JD | 2 |
| Garcia-España, F | 1 |
| Fawcett, J | 1 |
| Quitkin, FM | 2 |
| Reimherr, FW | 2 |
| Rosenbaum, JF | 2 |
| Schweizer, E | 1 |
| Beasley, C | 1 |
| Tiller, JW | 1 |
| Bouwer, C | 1 |
| Behnke, K | 1 |
| Tamura, RN | 1 |
| Sundell, KL | 1 |
| Michelson, D | 1 |
| Beasley, CM | 3 |
| Nilsson, ME | 1 |
| Koke, SC | 1 |
| Gonzales, JS | 1 |
| Usher, RW | 1 |
| Bosomworth, JC | 1 |
| Diamond, S | 1 |
| Freitag, FG | 1 |
| Feighner, JP | 1 |
| Cohn, JB | 1 |
| Saletu, B | 1 |
| Grünberger, J | 1 |
| Stark, P | 1 |
| Hardison, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020] | Phase 4 | 1,096 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| An Investigation of the Antidepressant Efficacy of a Dopamine Agonist With Neurotrophic Properties in Bipolar Disorder[NCT00025792] | Phase 2 | 200 participants | Interventional | 2001-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fluoxetine and Bilateral Headache
| Article | Year |
|---|---|
Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Delayed-Ac | 2008 |
Newer antidepressants and the discontinuation syndrome.
Topics: Adverse Drug Reaction Reporting Systems; Cyclohexanols; Dizziness; Fluoxetine; Headache; Humans; Inc | 1997 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Femal | 1997 |
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; H | 2000 |
17 trials available for fluoxetine and Bilateral Headache
| Article | Year |
|---|---|
Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depression; Dizziness; D | 2009 |
Citalopram treatment of fluoxetine-intolerant depressed patients.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Drug Tolerance; Female; Fluoxetine; Headache; Humans; | 2003 |
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsyc | 2007 |
Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Diagnostic and Statistical Manual of Mental Disorde | 2007 |
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depress | 2007 |
Fluoxetine and migraine: comparison of double-blind trials.
Topics: Chronic Disease; Double-Blind Method; Fluoxetine; Headache; Humans; Migraine Disorders; Multivariate | 1995 |
Double-blind trial of fluoxetine: chronic daily headache and migraine.
Topics: Adult; Affect; Chronic Disease; Double-Blind Method; Female; Fluoxetine; Headache; Humans; Male; Mid | 1994 |
Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients.
Topics: Adult; Benzamides; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Headache; Hum | 1996 |
Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group.
Topics: Adult; Combined Modality Therapy; Comorbidity; Depressive Disorder; Double-Blind Method; Drug Admini | 1998 |
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration | 1998 |
Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; C | 1998 |
Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.
Topics: Adult; Benzamides; Double-Blind Method; Female; Fluoxetine; Headache; Humans; Male; Moclobemide; Mon | 1999 |
Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
Topics: Anxiety; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Fluoxetine; Follow- | 1999 |
Efficacy and safety of morning versus evening fluoxetine administration.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Circadian Rhythm; Depressive Disorder; Double-Blind Meth | 1991 |
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder.
Topics: Age Factors; Aged; Anxiety; Blood Pressure; Body Weight; Clinical Trials as Topic; Depressive Disord | 1985 |
Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses.
Topics: Adult; Antidepressive Agents; Attention; Biological Availability; Blood Pressure; Brain; Clinical Tr | 1985 |
A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Clinical Trials as Topic | 1985 |
3 other studies available for fluoxetine and Bilateral Headache
| Article | Year |
|---|---|
Is generic fluoxetine effective?
Topics: Depressive Disorder; Fluoxetine; Headache; Humans; Randomized Controlled Trials as Topic; Selective | 2004 |
Clarification of the serotonin syndrome.
Topics: Antidepressive Agents, Second-Generation; Arousal; Fluoxetine; Headache; Humans; Serotonin; Sleep In | 1997 |
The use of fluoxetine in the treatment of headache.
Topics: Fluoxetine; Headache; Humans | 1989 |